Roflumilast
Roflumilast, sold under the trade name Daxas among others, is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (PDE-4). It has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease (COPD).In June 2010, it was approved in the European Union for severe COPD associated with chronic bronchitis. In February 2011, it gained FDA approval in the United States for reducing COPD exacerbations.

Medical uses
Roflumilast is indicated for the treatment of severe chronic obstructive pulmonary disease (COPD) and for the treatment of plaque psoriasis.It is used in the prevention of exacerbations (lung attacks) in severe chronic obstructive pulmonary disease (COPD).A topical formulation of Rolflumilast was recently approved by the U.S. Food and Drug Administration for plaque psoriasis.

Adverse effects
Common (1–10% incidence) adverse effects include:
Diarrhea
Weight loss
Nausea
Headache
Insomnia
Decreased appetite
Abdominal pain
Rhinitis
Sinusitis
Urinary tract infection
Depression

References
External links
"Roflumilast". Drug Information Portal. U.S. National Library of Medicine.